Type 1 Diabetes Trial, Recruiting NCT05498974 Sponsor: Second Xiangya Hospital of Central South University Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT05498974
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with type 1 diabetes at any point in their life, where the diagnosis was made by a specialist doctor.
  • People who were diagnosed with diabetes before the age of 15, were not overweight or obese at the time of diagnosis, have had a serious episode of diabetic ketoacidosis (a dangerous build-up of acids in the blood), and whose C-peptide levels (a marker of insulin production) have never exceeded 200 pmol/L.
  • People who started insulin treatment after their diabetes diagnosis and have continued using it (not counting pancreas or islet cell transplants), and who have tested positive for certain antibodies related to type 1 diabetes.
  • Children and teenagers who were diagnosed with any type of diabetes at age 20 or younger, regardless of how long they have had it.

Who may not be able to join:

  • Adults with type 1 diabetes who did not need insulin for at least the first 6 months after their diagnosis (this exclusion does not apply to those diagnosed at age 20 or younger).
  • Adults with type 1 diabetes who have had diabetes for more than one year and were able to go one month without insulin without experiencing diabetic ketoacidosis (confirm with trial site).
  • Adults with type 1 diabetes whose C-peptide levels (a measure of the body's own insulin production) have been higher than 800 pmol/L at any point.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zhiguang Zhou, MD, PhD, The Second Xiangya Hospital, Central South University

Phone: +8673185292154

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
1 January 2022
Est. completion
31 December 2035

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in serum hemoglobin A1c level; Albumin-to-creatinine ratio in urine sample; Arteriosclerotic cardiovascular diseases; Electromyography; PHQ-9; GAD-7; WHO-5; PAID

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov